Takeda Pharmaceutical (NYSE:TAK – Get a rating) and Genmab A/S (OTCMKTS: GNMSF – Get a rating) are both large-cap medical companies, but which is the better investment? We’ll compare the two companies based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, and analyst recommendations.
Valuation and benefits
This table compares revenue, earnings per share (EPS), and valuation of Takeda Pharmaceutical and Genmab A/S.
|Gross revenue||Price/sales ratio||Net revenue||Earnings per share||Price/earnings ratio|
|Pharmaceutical Takeda||$31.79 billion||1.44||$2.05 billion||$0.85||16.96|
|Genmab A/S||$1.35 billion||16.29||$478.57 million||$5.61||59.92|
Takeda Pharmaceutical has higher revenue and profit than Genmab A/S. Takeda Pharmaceutical trades at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Takeda Pharmaceutical has a beta of 0.7, suggesting its stock price is 30% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.79, suggesting its stock price is 21% less volatile than the S&P 500.
Insider and Institutional Ownership
2.4% of Takeda Pharmaceutical shares are held by institutional investors. By comparison, 0.0% of Genmab A/S shares are held by institutional investors. Strong institutional ownership indicates that endowments, hedge funds, and large fund managers believe a stock will outperform the market over the long term.
This table compares the net margins, return on equity and return on assets of Takeda Pharmaceutical and Genmab A/S.
|Net margins||Return on equity||return on assets|
This is a breakdown of current Takeda Pharmaceutical and Genmab A/S ratings, as reported by MarketBeat.
|Sales Ratings||Hold odds||Buy reviews||Strong buy odds||Rating|
|Genmab A/S||0||0||0||0||N / A|
Genmab A/S beats Takeda Pharmaceutical on 6 out of 11 factors compared between the two stocks.
About Takeda Pharmaceutical (Get a rating)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing and licensing of pharmaceutical products worldwide. It offers pharmaceutical products in the fields of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematological disorders, and hereditary angioedema, as well as plasma-derived therapies and vaccines. The Company offers its products under the brand names Entyvio, Gattex/Revestive, Alofisel, Natpara, Adynovate/Adynovi, Takhzyro, Elaprase, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Albumin/Flexbumin, Ninlaro and Alunbrig. Takeda Pharmaceutical Company has license agreements with Denali Therapeutics and Wave Life Sciences Ltd; collaboration agreements with Neurocrine Biosciences, Inc. and Rani Therapeutics LLC; licensing and research agreements with the University of Texas MD Anderson Cancer Center, Poseida Therapeutics, Inc. and Arrowhead Pharmaceuticals Inc.; research collaboration agreements with Arrowhead Pharmaceuticals Inc. and Ovid Therapeutics Inc.; and a collaboration with Evox Therapeutics Ltd., as well as a license agreement with ProThera Biologics Inc. It also has strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; HemoShear Therapeutics, LLC; KSQ therapy; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
About Genmab A/S (Get a rating)
Genmab A/S develops therapeutic antibodies for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers and AL amyloidosis; GEN1047; tisotumab vedotin for the treatment of cervical, ovarian and solid cancers; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB for the treatment of solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for the treatment of hematological malignancies. The company is also developing products, which are in Phase 2 include Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat Hodgkin’s lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to process MM; PRV-015 for the treatment of celiac disease; Mim8 for the treatment of haemophilia A; and Lu AF82422 for the treatment of multiple system atrophy. Additionally, it has about 20 active preclinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of mRNA-based differentiated antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Get news and reviews for Takeda Pharmaceutical Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Takeda Pharmaceutical and related companies with MarketBeat.com’s FREE daily email newsletter.